课题基金 / 基金详情

INTRAPERITONEAL INSULIN ADMINISTRATION IN DIABETES

INTRAPERITONEAL INSULIN ADMINISTRATION IN DIABETES
糖尿病腹膜内胰岛素给药
批准号:
3152393
负责人:
David S Schade
金额:
$15.67万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-07-01 至 1988-06-30

项目摘要

项目成果

David S Schade的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
During the last five years, an advancement in the treatment of the insulin dependent diabetic patient (Type I) has been the delivery of insulin into the peritoneal space. From our previous studies, five advantages of this insulin delivery route compared to the intravenous and subcutaneous routes have emerged: 1) prolonged insulin delivery catheter patency (more than five years), 2) direct portal vein insulin absorption (direct hepatic insulinzation), 3) decreased peripheral hyperinsulinemia, 4) rapid absorption of intraperitioneal insulin, resulting in normal meal insulin profiles, and 5) normalization of the plasma glucose concentration and glycosylated hemoglobin concentration. Having established the advantages of this route of insulin delivery, we now propose to expand our investigation to specific clinical settings. The grant is divided into three projects: 1) examination of the response and insulin kinetics of intraperitoneally delivered insulin in the fed, postprandial and exercising diabetic patient, 2) long-term follow-up (five years) of insulin-dependent diabetic subjects who have received insulin exclusively by the intraperitoneal route (these patients have all been implanted with our remotely-controlled insulin delivery pump whose insulin delivery catheter terminates in the peritoneal space), and 3) intraperitoneal insulin delivery in a subgroup of insulin-dependent diabetic patients who are resistant to subcutaneous insulin delivery. To safely administer intraperitoneal insulin into these latter patients, we have developed an implantable FDA-approved subcutaneous-peritoneal access device. The proposed studies will carefully define the kinetics of intraperitoneal insulin absorption in insulin-dependent diabetic patients. The long-term benefits to these patients may be the reduction in both microvascular diabetic complications (as a result of normoglycemia) and a reduction in the macrovascular-atherosclerotic complications (as a result of normal insulin profiles). Depending upon the results of the proposed studies, the intraperitioneal delivery of insulin may become the preferred insulin delivery route for specific insulin-requiring diabetic patients.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
Surgery and diabetes.
手术和糖尿病。
DOI: 10.1016/s0025-7125(16)30720-9
发表时间: 1988
期刊: The Medical clinics of North America
影响因子: --
作者: [Schade,DS]
通讯作者: Schade,DS
Human insulin crystals.
人胰岛素晶体。
DOI: --
发表时间: 1985
期刊: JAMA : the journal of the American Medical Association
影响因子: --
作者: [Schade,DS, DeLongo-Davis,J]
通讯作者: DeLongo-Davis,J
Use of a computerized glucose clamp technique to diagnose an insulinoma.
使用计算机葡萄糖钳夹技术诊断胰岛素瘤。
DOI: 10.7326/0003-4819-101-5-648
发表时间: 1984
期刊: Annals of internal medicine
影响因子: 39.2
作者: [Reynolds,JH, Kaminsky,NI, Schade,DS, Eaton,RP]
通讯作者: Eaton,RP
Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial.
在胰岛素治疗中添加磺酰脲类药物治疗控制不佳的 II 型糖尿病。
DOI: --
发表时间: 1987
期刊: JAMA
影响因子: --
作者: [Schade,DS, Mitchell,WJ, Griego,G]
通讯作者: Griego,G
Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy.
  • 批准号:
    10007575
  • 项目类别:
  • 资助金额:
    $98.91万
  • 财政年份:
    2015
  • 负责人:
    David S Schade
  • 依托单位:
Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy.
  • 批准号:
    10400917
  • 项目类别:
  • 资助金额:
    $95.59万
  • 财政年份:
    2015
  • 负责人:
    David S Schade
  • 依托单位:
EPIDEMIOLOGY OF DIABETES INTERVENTION AND COMPLICATIONS (EDIC)
  • 批准号:
    8166641
  • 项目类别:
  • 资助金额:
    $0.51万
  • 财政年份:
    2009
  • 负责人:
    David S Schade
  • 依托单位:
THE IMPORTANCE OF INSULIN TIMING IN TYPE 1 DIABETES
  • 批准号:
    8166628
  • 项目类别:
  • 资助金额:
    $3.29万
  • 财政年份:
    2009
  • 负责人:
    David S Schade
  • 依托单位:
海外基金